论文部分内容阅读
目的探讨补中益气汤对A549/DDP及A549细胞株荷瘤裸鼠移植瘤的的抑瘤作用及对MRP蛋白表达影响。方法体外培养A549/DDP及A549细胞,接种于BALB/c nu/nu裸鼠腋窝皮下,荷瘤成功后给予低、中、高剂量补中益气汤治疗。测量移植瘤体积并计算药物抑瘤率,蛋白质印迹法检测移植瘤组织MRP蛋白的表达。结果顺铂使A549/DDP移植瘤体积无显著变化(P>0.05),而A549移植瘤体积显著缩小(P<0.05);联合补中益气汤使A549/DDP及A549移植瘤体积均缩小(P<0.05),抑瘤率均增加(P<0.05),随着中药剂量的增加,移植瘤体积逐渐缩小,抑瘤率逐渐增加;顺铂上调A549/DDP移植瘤组织中MRP蛋白表达(P<0.05),下调A549移植瘤组织中MRP蛋白表达(P<0.05);联合补中益气汤使A549/DDP及A549移植瘤组织中MRP蛋白表达均下调(P<0.05),随着中药剂量的增加,MRP蛋白水平越来越低。结论补中益气汤可有效减小移植瘤体积,增加顺铂的抑瘤率,下调MRP蛋白表达,且在顺铂敏感及顺铂耐药的肺癌组织中均有疗效。
Objective To investigate the inhibitory effect of Buzhong Yiqi Decoction on A549 / DDP and A549 cell lines in nude mice transplanted tumor and its effect on MRP protein expression. Methods A549 / DDP and A549 cells were cultured in vitro and inoculated subcutaneously into the armpit of BALB / c nu / nu nude mice. After the tumor was successfully treated, low, medium and high dose Buzhong Yiqi Decoction was given. The volume of tumor xenografts was measured and the tumor inhibition rate was calculated. The expression of MRP protein in xenografts was detected by Western blotting. Results Cisplatin had no significant changes in the volume of A549 / DDP xenografts (P> 0.05), while the volume of A549 xenografts was significantly reduced (P <0.05). The volume of A549 / DDP and A549 xenografts was decreased with cisplatin (P <0.05). The tumor inhibition rate was increased (P <0.05). With the increase of the dose of traditional Chinese medicine, the volume of tumor was gradually reduced and the tumor inhibition rate increased gradually. Cisplatin up-regulated the expression of MRP in A549 / <0.05), and down-regulated the expression of MRP protein in A549 xenografts (P <0.05). The expression of MRP in A549 / DDP and A549 xenografts was decreased with Bu Zhong Yi Qi decoction (P <0.05) MRP protein levels are getting lower and lower. Conclusion Buzhong Yiqi Decoction can effectively reduce the tumor volume, increase the inhibitory rate of cisplatin and down-regulate the expression of MRP protein, and are effective in cisplatin-sensitive and cisplatin-resistant lung cancer tissues.